metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
	pembrolizumab alone
	KEYNOTE-048 (P vs C ; all population), 2019 Lancet 2019; 394:1915-1928 Adv Ther 2021 Apr 15. J Clin Oncol 2022; 40:2321-2332-. NCT02358031	RCT	mHNSCC - L1 - all population	pembrolizumab	cetuximab with chemotherapy (platine plus 5FU)	patients with recurrent or metastatic squamous cell carcinoma of the head and neck, untreated locally incurable recurrent or metastatic HNSCC	301 / 300	some concern	inconclusive
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
	pembrolizumab alone
	KEYNOTE-048 (P vs C ; CPS > 20), 2019 Lancet 2019; 394:1915-1928 Adv Ther 2021 Apr 15. NCT02358031	RCT	mHNSCC - L1 - PDL1 positive	pembrolizumab	cetuximab with chemotherapy (platine plus 5FU)	patients with recurrent or metastatic squamous cell carcinoma of the head and neck, untreated locally incurable recurrent or metastatic HNSCC	133 / 122	some concern	conclusif
	KEYNOTE-048 (P vs C ; CPS > 1), 2019 Lancet 2019; 394:1915-1928 Adv Ther 2021 Apr 15. NCT02358031	RCT	mHNSCC - L1 - PDL1 positive	pembrolizumab	platinium based chemotherapy (cetuximab plus 5FU and platine)	patients with recurrent or metastatic squamous cell carcinoma of the head and neck, untreated locally incurable recurrent or metastatic HNSCC	257 / 255	some concern	conclusif
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-040 (all population), 2018 Lancet 2019; 393:156-167 BMJ Open 2020 Dec 18;10(12):e038867. J Immunother Cancer 2019 Apr 3;7(1):96. Mod Pathol 2020 Nov 25. NCT02252042	RCT	mHNSCC - L2 - all population	pembrolizumab	chemotherapy (methotrexate, docetaxel or cetuximab)	patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : all population	247 / 248	some concern	conclusif
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-040 (CPS >1), 2018 Lancet 2019; 393:156-167 BMJ Open 2020 Dec 18;10(12):e038867. J Immunother Cancer 2019 Apr 3;7(1):96. Mod Pathol 2020 Nov 25. NCT02252042	RCT	mHNSCC - L2 - PDL1 positive	pembrolizumab	chemotherapy (methotrexate, docetaxel or cetuximab)	patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : only patients with CPS > 1	196 / 191	some concern	conclusif